Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Aetna Inc.
Headquarters: Hartford, CT, United States of America
Website: N/A
Year Founded: 1850
Status: Acquired
BioCentury | Oct 31, 2020
Product Development
ICER’s influence on payers could translate to a seat at the table for government drug reviews
ICER’s focus on value-based pricing has positioned it to be a major voice on drug pricing in the U.S., whoever wins the election
BioCentury | Dec 13, 2019
Company News
CVS program seeks to encourage genetic testing of cancer patients
BioCentury | Aug 31, 2019
Product Development
Digital health: payers are figuring out what it’s worth
Back to School 2019: The first payer models for digital therapeutics are coming into view next year
BioCentury | Aug 10, 2019
Product Development
Payers’ view of reimbursement when gene therapy isn’t enough
SMA will be a testing ground for when and if payers reimburse for combinations involving a gene therapy
BioCentury | Jul 9, 2019
Financial News
July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more
BioCentury | Feb 23, 2019
Tools & Techniques
Modeling now for precision later
How GNS wants to make pay-for-performance unnecessary
BioCentury | Sep 29, 2018
Product Development
Deferred differentiation in migraine
How the anti-CGRP reimbursement landscape could shape in the near and long term
BioCentury | Sep 21, 2018
Politics, Policy & Law
Filling the rebate void
Why eliminating rebates might be a good but short term fix to lower drug prices
BioCentury | Sep 1, 2018
Politics, Policy & Law
Back to School 2018: A pathway to Biopharma 3.0
Back to School 2018: How external disrupters will drive biopharma to new business model
Items per page:
1 - 10 of 86